Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.

Perahia DG, Wang F, Mallinckrodt CH, Walker DJ, Detke MJ.

Eur Psychiatry. 2006 Sep;21(6):367-78. Epub 2006 May 11.

PMID:
16697153
2.

Duloxetine: a review of its use in the treatment of generalized anxiety disorder.

Carter NJ, McCormack PL.

CNS Drugs. 2009;23(6):523-41. doi: 10.2165/00023210-200923060-00006. Review.

PMID:
19480470
3.

Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials.

Hudson JI, Wohlreich MM, Kajdasz DK, Mallinckrodt CH, Watkin JG, Martynov OV.

Hum Psychopharmacol. 2005 Jul;20(5):327-41. Review.

PMID:
15912562
4.

Patterns of depressive symptom response in duloxetine-treated outpatients with mild, moderate or more severe depression.

Shelton RC, Prakash A, Mallinckrodt CH, Wohlreich MM, Raskin J, Robinson MJ, Detke MJ.

Int J Clin Pract. 2007 Aug;61(8):1337-48. Review.

PMID:
17627710
5.

Efficacy, safety and tolerability of duloxetine 60 mg once daily in major depression.

Cowen PJ, Ogilvie AD, Gama J.

Curr Med Res Opin. 2005 Mar;21(3):345-56. Review.

PMID:
15811202
6.

A non-inferiority comparison of duloxetine and venlafaxine in the treatment of adult patients with generalized anxiety disorder.

Allgulander C, Nutt D, Detke M, Erickson J, Spann M, Walker D, Ball S, Russell J.

J Psychopharmacol. 2008 Jun;22(4):417-25. doi: 10.1177/0269881108091588.

PMID:
18635722
7.

Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician.

Reddy S, Kane C, Pitrosky B, Musgnung J, Ninan PT, Guico-Pabia CJ.

Curr Med Res Opin. 2010 Jan;26(1):139-50. doi: 10.1185/03007990903408678. Review.

PMID:
19919295
8.

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.

Hunziker ME, Suehs BT, Bettinger TL, Crismon ML.

Clin Ther. 2005 Aug;27(8):1126-43. Review.

PMID:
16199241
9.

[Efficacy and tolerability of escitalopram in anxiety disorders: a review].

Pelissolo A.

Encephale. 2008 Sep;34(4):400-8. doi: 10.1016/j.encep.2008.04.004. Epub 2008 Aug 15. Review. French.

PMID:
18922243
10.

Newer antidepressants: review of efficacy and safety of escitalopram and duloxetine.

Hirschfeld RM, Vornik LA.

J Clin Psychiatry. 2004;65 Suppl 4:46-52. Review.

11.

Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression.

Dunner DL, D'Souza DN, Kajdasz DK, Detke MJ, Russell JM.

J Affect Disord. 2005 Jul;87(1):115-9. Review.

PMID:
15967235
12.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
13.

Duloxetine: a dual reuptake inhibitor.

Dugan SE, Fuller MA.

Ann Pharmacother. 2004 Dec;38(12):2078-85. Epub 2004 Nov 2. Review.

PMID:
15522980
14.

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S.

Curr Pharm Des. 2005;11(12):1475-93. Review.

PMID:
15892657
15.

[Sexual dysfunction with antidepressive agents. Effect of the change to amineptine in patients with sexual dysfunction secondary to SSRI].

Montejo AL, Llorca G, Izquierdo JA, Carrasco JL, Daniel E, Pérez-Sola V, Vicens E, Bousoño M, Sánchez-Iglesias S, Franco M, Cabezudo A, Rubio V, Ortega MA, Puigdellivol M, Domenech JR, Allué B, Sáez C, Mezquita B, Gálvez I, Pacheco L, de Miguel E.

Actas Esp Psiquiatr. 1999 Jan-Feb;27(1):23-34. Review. Spanish.

PMID:
10380144
16.

A systematic review of duloxetine for osteoarthritic pain: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

Citrome L, Weiss-Citrome A.

Postgrad Med. 2012 Jan;124(1):83-93. doi: 10.3810/pgm.2012.01.2521. Review.

PMID:
22314118
17.

Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.

Westanmo AD, Gayken J, Haight R.

Am J Health Syst Pharm. 2005 Dec 1;62(23):2481-90. Review.

PMID:
16303903
18.
19.

Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder.

Kirwin JL, Gören JL.

Pharmacotherapy. 2005 Mar;25(3):396-410. Review.

PMID:
15843287
20.

Safety and adverse event profile of duloxetine.

Wernicke JF, Gahimer J, Yalcin I, Wulster-Radcliffe M, Viktrup L.

Expert Opin Drug Saf. 2005 Nov;4(6):987-93. Review.

PMID:
16255658

Supplemental Content

Support Center